Firstly, in the Phase 3 ENHANCE-1 and ENHANCE-2 trials, ensifentrine reported a 36% and 42% pbo-adjusted reduction in COPD exacerbation at week 24, respectively. In contrast, dupixent demonstrated a 30% pbo-adjusted reduction in COPD exacerbation at week 52 in the BOREAS trial.
Verona Pharma is expected to submit an NDA by 1H 2023, PDUFA by 1H 2024, and launch in the US by 2H 2024.
COPD is a crowded place - not sure about what is special about their drug?
Unless this drug is better than other COPD drugs - this co is fully priced @ $2 B
This co cannot market the product even if approved - so it needs to be bought out but it will not get more than $3 B - so maybe 50% premium from here
Verona Pharma Announces Proposed Underwritten Public Offering Of 10M ADSs
4:42 pm ET August 9, 2022 (Benzinga) Print
Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares ("ADSs"), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share (the "Offering"). All ADSs in the Offering will be offered by Verona Pharma. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. In addition, Verona Pharma intends to grant the underwriters of the Offering a 30-day option to purchase up to an additional 1.5 million ADSs at the public offering price, less the underwriting discount and commission.
VRNA...$7.32...on the Gappa...Psar flipped Bullish yesterday...Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
$40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company)
Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties
Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China...https://www.otcmarkets.com/stock/VRNA/news/story?e&id=1919123 ...Should be a great trader today...imo...we shall see...:partying_face:
This thing is moving back to $6 and has a huge potential runway, even analysts are saying $34-$50 a share - I always cut their projections in half especially wedbush (who held 70,000 shares as of march 31st).
That still leaves us with a 5x potential over medium to long term - this thing can dance with news buckle up.
This thing at $60 yet?
Ok well good luck buddy
It’s a big board stock. Company can’t dilute without filing with SEC and notifying shareholders.
No, company diluting I wouldn’t buy this now. Wait buy cheaper if you must
Enough with the self promoting. “Let another man’s lips praise you and not your own.” There’s a great feature for anyone who doesn’t know it if you click someone’s profile you can ignore them forever on every board if you want to. I’m about to use that feature, lol.
Listen to me next time I will make you rich. Sell Sell Sell IMHO
I’m laughing.... What a pitty
That moron said sell at $9.50 why didn’t you guys listen to the idiot? Lol Ooooops
Ignore that moron and you will lose all your money. Just saying
Don’t sweat that moron. We Have a good thing here, IMO. The news was great and will get better over the coming months and years if you have patience. I’m sure at some point there will be an offering to pay for phase 3 operations? Or maybe they will find other financing options with their new finance/investment superstar they brought on board. This will go way up sometime soon whenever the MMs decide to stop playing games.
This is not me saying, this is analyst saying it. Big difference. I am laughing because you tend to follow me around, but that is ok, the more you follow me around, I see that you didn't follow me on CP*AH, some picks I make bank and some picks go against me, no one is perfect, no one, not even the analyst in their projects. But the bottom line still remains, COPD is a huge market, when the dust settles it will move North when you least expect it, heck I predicted 80 dollars on CR*TX and hit a few dollars just under that, I predicted CP*AH will hit between 2-3 dollars and possibly $5 and it went well over 5 dollars yesterday, heck I predicted LL*EX could be bought out for a premium and they just had an offer on the table for 25 cents well under my prediction, but heck at least I said they could get bought out, the shareholder have no choice but to sell if for that price. No one is perfect in the world trading, but at least I am 70% accurate with my predictions, to me, that is enough to make a good solid returns on annual basis. For now, you can go to trading OTC.
Let’s see where you’re in a week from today.
Hey I’m adding right now.
How long you going to bleed out?
Again, I could not care less what you say.
Ha ha ha ...listening to you?
What fool gonna do that.
Bet you wish you listened. Offering coming IMO
You just like to listen to yourself ain’t that right?!
That’s exactly the explanation!
Great time to add obviously.
“ Low volume shake down, simple as that. We just had another price target raised from $28.00 to $34. This is being manipulated by the big boys to exhaust traders, some tickers are not meant to have momo traders on it, this will rise in a stair step fashion. The fact still remains they have enough cash to last them till September 2020 and a fantastic data was released on Sunday for a huge market. People sell based on emotions, not on fundamentals. Plain and simple. ”
Low volume shake down, simple as that. We just had another price target raised from $28.00 to $34. This is being manipulated by the big boys to exhaust traders, some tickers are not meant to have momo traders on it, this will rise in a stair step fashion. The fact still remains they have enough cash to last them till September 2020 and a fantastic data was released on Sunday for a huge market. People sell based on emotions, not on fundamentals. Plain and simple.